Accelerating Success
From start-up to standout.
We provide start-ups with a structured and comprehensive toolkit for development, milestone achievement and eventual autonomy. Take a look at a few of the success stories from our growing portfolio of diverse and exciting companies.
Technology:
To develop new medical countermeasure for nerve agent exposure
To develop new medical countermeasure for nerve agent exposure
Developing novel therapeutics for metabolic disorders.
Source:
Case Western Reserve University, University of Texas Southwestern Medical Center
Technology:
First-in-class therapies for enhancing tissue repair and regeneration
Series A:
$5.9M
Investment Date:
Q3 2017
First-in-class therapies for enhancing tissue repair and regeneration
Source:
University of Minnesota
Technology:
Oncology: A new class of therapies to break drug resistance in cancer
Series A:
$7M
Investment Date:
Q4 2016
A new class of therapies to break drug resistance in cancer
Source:
MD Anderson Cancer Center
Technology:
Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death.
Series A:
$31M
Investment Date:
Q3 2018
Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death.
Source:
The Rockefeller University
Technology:
New generation of natural product derived therapeutics for human disease.
Series A:
$20M
Investment Date:
Q1 2016
New generation of natural product derived therapeutics for human disease.
Source:
Weill Cornell Medicine
Technology:
Novel approach to therapeutics for cancer and metabolic diseases.
Series A:
$48M
Investment Date:
Q1 2016
Graduation Date:
Q3 2017
Novel approach to therapeutics for cancer and metabolic diseases.
Source:
Entepreneur
Technology:
Oncology: Novel immunotherapy approach and targets for mAbs
Series A:
$5.3M
Investment Date:
Q2 2011
Source:
Johns Hopkins, Wistar Institute
Technology:
Oncology, Metabolic, CNS: Small molecule inhibitors of histone acetyl transferases (HAT’s)
Series A:
$4.4M
Investment Date:
Q4 2010
Follow On $:
$5.85M
Source:
University of Washington
Technology:
Antibody platform: Novel method for rapidly developing high affinity mAbs
Series A:
$4.4M
Investment Date:
Q2 2009
Graduation Date:
Q3 2011
Follow On $:
SOLD
Source:
Nanogen, Inc
Technology:
Oncology, Hematopoeitic Disorders: microRNA inhibition platform solving distribution and delivery
Series A:
$3.5M
Investment Date:
Q3 2008
Graduation Date:
Q4 2011
Follow On $:
$9.9M
Source:
California Institute of Tech.
Technology:
Small molecule GPCR Inhibitors: Next generation in-silico drug design platform
Series A:
$4.5M
Investment Date:
Q2 2008
Source:
Washington State University
Technology:
Oncology: Novel target to prevent tumor invasion and metastasis
Series A:
$1.5M
Investment Date:
Q1 2008
Source:
University of Washington
Technology:
Ischemia/Reperfusion: Recombinant protein effective in-vivo at rescuing I/R injury.
Series A:
$4.5M
Investment Date:
Q2 2006
Follow On $:
$2M
Source:
California Institute of Tech.
Technology:
Multiple Indications: Platform for specific improvement of recombinant proteins and mAbs
Series A:
$3.4M
Investment Date:
Q4 2005
Graduation Date:
Q4 2007
Follow On $:
$39M
Source:
Institute for Systems Biology
Technology:
Clinical Diagnostics: Biomarker platform for discovery of blood circulating biomarkers indicative of organ disease
Series A:
$5M
Investment Date:
Q3 2005
Graduation Date:
Q3 2009
Follow On $:
$30.4M
Source:
Entepreneur
Technology:
Oncology, Infectious Disease: Platform for the discovery of novel mAbs against cancers and pathogens
Series A:
$2M
Investment Date:
Q4 2004
Graduation Date:
Q2 2007
Follow On $:
$33.4M
Source:
Entepreneur
Technology:
Autoimmunity/Inflammation: Platform for discovery of new autoimmune and inflammatory targets.
Series A:
$4.8M
Investment Date:
Q2 2004
Graduation Date:
Q2 2006
Follow On $:
$45.1M
Source:
Iowa State University
Technology:
Infectious Disease: Platform for development of vaccines against many pathogens
Series A:
$1.6M
Investment Date:
Q1 2004